What is Abb-R-CHOP used for?

Abb-R-CHOP is indicated for Non-Hodgkin lymphoma.

Who makes Abb-R-CHOP?

Abb-R-CHOP is developed by Asan Medical Center.

What are the side effects of Abb-R-CHOP?

Common side effects include Neutropenia, Thrombocytopenia, Anemia, Infection, Fatigue.

Last reviewed 2026-04-23 · How we verify

Abb-R-CHOP

Asan Medical Center · Phase 2 active Small molecule

Abb-R-CHOP is a combination chemotherapy regimen that targets rapidly dividing cancer cells.

Abb-R-CHOP is a combination chemotherapy regimen that targets rapidly dividing cancer cells. Used for Non-Hodgkin lymphoma.

At a glance

Generic name	Abb-R-CHOP
Sponsor	Asan Medical Center
Drug class	Chemotherapy regimen
Target	CD20
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 2

Mechanism of action

It combines the anti-CD20 monoclonal antibody rituximab with the chemotherapy agents cyclophosphamide, doxorubicin, vincristine, and prednisone. This combination works by inducing cell death in rapidly dividing cancer cells, such as those found in non-Hodgkin lymphoma.

Approved indications

Non-Hodgkin lymphoma

Common side effects

Neutropenia
Thrombocytopenia
Anemia
Infection
Fatigue

Key clinical trials

Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results